Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bintrafusp alfa + docetaxel
- Development stage
- Phase 2
- Lead developer
- Merck KGaA
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bintrafusp alfa + docetaxel is a **combination therapy** consisting of bintrafusp alfa, a bifunctional fusion protein targeting both programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β), and docetaxel, a cytotoxic taxane chemotherapeutic agent. Bintrafusp alfa acts by simultaneously blocking PD-L1-mediated immune evasion and trapping/sequestering TGF-β in the tumor microenvironment, thus reversing immunosuppression, enhancing T cell and NK cell antitumor activity, and inhibiting epithelial-mesenchymal transition (EMT) and chemotherapy resistance[2][4][7]. Docetaxel promotes microtubule stabilization and thereby inhibits mitosis, resulting in cancer cell death. This combination is being evaluated in clinical trials for several advanced solid tumors, including metastatic prostate cancer and non-small cell lung cancer (NSCLC), aiming to increase progression-free survival and response rates over chemotherapy or immunotherapy alone[1][3][7].
- Other names
- bintrafusp alfa + docetaxel
02
Targets
MicrotubuleCD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bintrafusp alfa + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bintrafusp alfa + docetaxel.